Company profile: Cristal Therapeutics
1.1 - Company Overview
Company description
- Provider of nanomedicine and bioconjugation technologies based on proprietary polymeric platforms. Offers CriPec, a nanomedicine platform for targeted treatment of cancer and other diseases with patient stratification via non-invasive imaging; CliCr, copper-free click chemistry for stable bioconjugates; and CriVac, a vaccine platform combining CliCr with OMV, including for SARS-CoV-2.
Products and services
- CriPec®: A proprietary nanomedicine platform engineered for targeted treatment of cancer and other diseases using polymeric technologies, enabling patient stratification via non-invasive imaging and combining new or existing drugs
- CliCr®: A copper-free click-chemistry technology producing faster, more stable bioconjugate reactions for various diagnostic and therapeutic applications
- CriVac®: An OMV-based vaccine platform that combines CliCr® technology to develop novel vaccines, including those targeting SARS-CoV-2
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cristal Therapeutics
Cinfa Biotech
HQ: Spain
Website
- Description: Provider of biosimilars development and manufacturing exclusively in Europe, adhering to strict guidelines and highest European quality standards with specialist know-how. Founded in 2013 as part of the Spanish Cinfa Group; active in the global biosimilars market and currently has two products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinfa Biotech company profile →
Alethia Biotherapeutics
HQ: Canada
Website
- Description: Provider of monoclonal antibody-based therapeutics for cancer-associated diseases, including AB-16B5, a humanized IgG2 antibody targeting secreted clusterin to inhibit EMT, enhance chemotherapy response, and reduce tumor invasion; AB-3A4, developed as an ADC targeting KAAG1 for ovarian and triple-negative breast cancers; and STAR technology for discovering differentially expressed mRNA sequences, including rare ones, to identify novel therapeutic targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alethia Biotherapeutics company profile →
Foundation Medicine
HQ: United States
Website
- Description: Provider of molecular information and clinical diagnostic tests for personalized cancer care, including FoundationOne CDx tissue-based comprehensive genomic profiling, FoundationOne Liquid CDx blood-based ctDNA profiling, FoundationOne Heme for hematologic malignancies, FoundationOne RNA fusion detection in solid tumors, the FoundationCore cancer genomic database, and Molecular Tumor Boards.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foundation Medicine company profile →
Nerviano Medical Sciences
HQ: Italy
Website
- Description: Provider of oncology research and development services, including drug discovery, preclinical research, clinical development, and manufacturing, serving local and international markets. Offers Entrectinib, a kinase inhibitor for ROS1 fusion–positive lung cancer and NTRK gene fusion solid tumors, designed to cross the blood–brain barrier and address CNS metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerviano Medical Sciences company profile →
Rovers
HQ: The Netherlands
Website
- Description: Provider of cancer-screening medical devices, designing, developing, and manufacturing self-sampling and diagnostic tools including Evalyn Brush for at-home HPV screening; Anex Brush for anal cancer screening; Orcellex Brush for oral cancer screening; Viba-Brush and Delphi Screener for cervical cancer self-sampling; and Cervex-Brush for comprehensive cervical cell collection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rovers company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cristal Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cristal Therapeutics
2.2 - Growth funds investing in similar companies to Cristal Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cristal Therapeutics
4.2 - Public trading comparable groups for Cristal Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →